metaEvidence - overview


			deaths (OS)
mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population
versus ipilimumab alone
	nivolumab alone vs. ipilimumab alone	1	0.63 [0.48; 0.82], 1 RCT, I2=0% conclusive unassessable degree of certainty
	nivolumab plus ipilimumab vs. ipilimumab alone	2	0.58 [0.46; 0.74], 2 RCTs, I2=0% conclusive high degree of certainty
versus ipilimumab followed by nivolumab
	nivolumab followed by ipilimumab vs. ipilimumab followed by nivolumab	1	0.48 [0.29; 0.80], 1 RCT, I2=0% unassessable degree of certainty
versus nivolumab alone
	nivolumab plus ipilimumab vs. nivolumab alone	1	0.65 [0.53; 0.80], 1 RCT, I2=0% unassessable degree of certainty
	relatlimab plus nivolumab vs. nivolumab alone	1	-
versus Standard of Care (SoC)
	tremelimumab vs. Standard of Care (SoC)	1	0.88 [0.75; 1.04], 1 RCT, I2=0% inconclusive result